Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ursula A Matulonis

Showing results (11-20 of 236) with videos related to

Pageof 24
Sort By:
Clinical Advances in Hematology & Oncology : H&O|April 7, 2022
Immunotherapy for ovarian cancerRebecca Porter, Ursula A Matulonis
Clinical Advances in Hematology & Oncology : H&O|March 28, 2025
Update on PARP inhibitors for the treatment of ovarian cancerJoyce Liu, Ursula A Matulonis
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 17, 2026
Antibody-Drug Conjugates in Gynecologic Oncology: Advances, Challenges, and Future DirectionsTaliya Lantsman, Ursula A Matulonis
Med (New York, N.Y.)|October 11, 2025
Targeting the glucocorticoid receptor as a therapeutic strategy for ovarian cancer: The ROSELLA studyTaliya Lantsman, Ursula A Matulonis
Frontiers in Oncology|December 31, 2013
Current status and evolution of preclinical drug development models of epithelial ovarian cancerPanagiotis A Konstantinopoulos, Ursula A Matulonis
Nature Cancer|August 31, 2023
Clinical and translational advances in ovarian cancer therapyPanagiotis A Konstantinopoulos, Ursula A Matulonis
Hematology/Oncology Clinics of North America|November 5, 2018
Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian CancerPanagiotis A Konstantinopoulos, Ursula A Matulonis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2021
Checkpoint Blockade: Not Yet NINJA Status in Ovarian CancerRebecca L Porter, Ursula A Matulonis
Gynecologic Oncology|March 27, 2016
Precision medicineRobert L Coleman, Ursula A Matulonis
Current Oncology Reports|March 18, 2016
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?Joyce F Liu, Ursula A Matulonis
Pageof 24

Showing results (11-20 of 236) with videos related to

Sort By:
Pageof 24
Clinical Advances in Hematology & Oncology : H&O|April 7, 2022
Immunotherapy for ovarian cancerRebecca Porter, Ursula A Matulonis
Clinical Advances in Hematology & Oncology : H&O|March 28, 2025
Update on PARP inhibitors for the treatment of ovarian cancerJoyce Liu, Ursula A Matulonis
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 17, 2026
Antibody-Drug Conjugates in Gynecologic Oncology: Advances, Challenges, and Future DirectionsTaliya Lantsman, Ursula A Matulonis
Med (New York, N.Y.)|October 11, 2025
Targeting the glucocorticoid receptor as a therapeutic strategy for ovarian cancer: The ROSELLA studyTaliya Lantsman, Ursula A Matulonis
Frontiers in Oncology|December 31, 2013
Current status and evolution of preclinical drug development models of epithelial ovarian cancerPanagiotis A Konstantinopoulos, Ursula A Matulonis
Nature Cancer|August 31, 2023
Clinical and translational advances in ovarian cancer therapyPanagiotis A Konstantinopoulos, Ursula A Matulonis
Hematology/Oncology Clinics of North America|November 5, 2018
Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian CancerPanagiotis A Konstantinopoulos, Ursula A Matulonis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2021
Checkpoint Blockade: Not Yet NINJA Status in Ovarian CancerRebecca L Porter, Ursula A Matulonis
Gynecologic Oncology|March 27, 2016
Precision medicineRobert L Coleman, Ursula A Matulonis
Current Oncology Reports|March 18, 2016
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?Joyce F Liu, Ursula A Matulonis
Pageof 24